TACSTD2 and neoplasm: The evolution of ADC target selection has progressed from hematologic-specific CD antigens (e.g., CD30, CD22, CD33, CD79b) to tumor-associated antigens more commonly expressed in solid tumors, such as HER2, TROP2, Nectin-4, and folate receptor α [20, 47].